Multiple China Biotech VC, PE Deals Kick Off A Strong Start To 2024

Jiangsu Vcare Pharmatech, Neurodawn Pharmaceutical and Shanghai Synvida Biotechnology stand out with funding rounds that each grossed roughly CNY200m ($28m) and above.

funding
Venture capital and private quity funding for Chinese biotechs got off to a good start in January. • Source: Shutterstock

More from China

More from Focus On Asia